Technical Analysis for CRNX - Crinetics Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 17.32 5.48% 0.90
CRNX closed up 5.48 percent on Thursday, April 15, 2021, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical CRNX trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 5.48%
Crossed Above 20 DMA Bullish 5.48%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 5.48%
Calm After Storm Range Contraction 5.48%
Inside Day Range Contraction 5.48%
Fell Below 20 DMA Bearish 8.11%
50 DMA Support Bullish 8.11%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 8.11%
20 DMA Support Bullish 1.23%
180 Bullish Setup Bullish Swing Setup 1.23%
Older End-of-Day Signals for CRNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 17 hours ago
Rose Above Upper Bollinger Band about 18 hours ago
Upper Bollinger Band Resistance about 18 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Up 5% about 19 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Crinetics Pharmaceuticals, Inc. Description

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organ Systems Disease Endocrine System Insulin Stage Pharmaceutical Pancreatic Cancer Chemical Entities Acromegaly Endocrine Disease Neuroendocrine Tumor Neuroendocrine Tumors Endocrine Diseases Neuroendocrinology

Is CRNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.7
52 Week Low 11.61
Average Volume 142,628
200-Day Moving Average 15.00
50-Day Moving Average 16.11
20-Day Moving Average 16.32
10-Day Moving Average 16.68
Average True Range 1.14
ADX 12.12
+DI 24.24
-DI 18.80
Chandelier Exit (Long, 3 ATRs ) 15.83
Chandelier Exit (Short, 3 ATRs ) 18.25
Upper Bollinger Band 17.59
Lower Bollinger Band 15.05
Percent B (%b) 0.89
BandWidth 15.55
MACD Line 0.27
MACD Signal Line 0.21
MACD Histogram 0.0594
Fundamentals Value
Market Cap 570.21 Million
Num Shares 32.9 Million
EPS -1.62
Price-to-Earnings (P/E) Ratio -10.69
Price-to-Sales 942.40
Price-to-Book 2.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.94
Resistance 3 (R3) 18.85 18.21 18.67
Resistance 2 (R2) 18.21 17.80 18.26 18.58
Resistance 1 (R1) 17.77 17.55 17.99 17.86 18.49
Pivot Point 17.13 17.13 17.25 17.18 17.13
Support 1 (S1) 16.69 16.72 16.91 16.78 16.15
Support 2 (S2) 16.05 16.47 16.10 16.06
Support 3 (S3) 15.61 16.05 15.97
Support 4 (S4) 15.70